Advancements in Antidiabetic Therapy: An extensive study on the use of Polypills to treat type 2 diabetes

Parimita Kalita1,2*, Rajesh Jesudasan2 and Chinmay Maut1

Keywords: Polypill; Type2 Diabetes; Combination Pills

Introduction

T2DM, also known as non-insulin-dependent diabetes mellitus or adult-onset diabetes, is a metabolic condition characterized by elevated blood glucose levels due to insulin resistance and relative insulin shortage. T2DM symptoms include frequent urination, increased thirst, lethargy, and weight loss. T2DM is caused by a mix of hereditary and environmental factors. Toxins in the environment may also be contributing to recent rises in the rate of T2DM. Having T2DM relatives significantly raises the likelihood of acquiring T2DM in the family. In addition to any genetic component, environmental factors, particularly nutrition and obesity, have a significant role in the development of T2DM. Insulin resistance occurs when human tissues do not respond effectively to insulin [1].

T2DM is a heterogeneous and progressive metabolic illness characterized by hyperglycaemia and induced by abnormalities in insulin secretion or action as a result of a complicated network of clinical circumstances. There are numerous pathways that interact and mutually reinforce each other, increasing the risk of other diseases such as heart disease, peripheral arterial and cerebrovascular disease, obesity, and non-alcoholic fatty liver disease, among others. Diabetes mellitus (DM) is one of the most ancient diseases known to man. About 3000 years ago, it was first mentioned in an Egyptian manuscript. Type 2 diabetes mellitus (T2DM) is by far the most prevalent kind of diabetes, followed by type 1 diabetes mellitus and gestational diabetes [2].

Dysregulation of the metabolism of carbohydrates, lipids, and proteins is a hallmark of type 2 diabetes, which is brought on by either decreased insulin production, insulin resistance, or both. Type 2 diabetes is brought on by the interplay of behavioural, environmental, and genetic risk factors [2]. T2DM epidemiology is influenced by both genetics and the environment. Following exposure to an environment characterized by sedentary behaviour and high calorie intake, genetic variables take influence. Globally, the number of adult patients affected by T2D was anticipated to be 537 million in 2021, with a further increase to 783 million by 2045. T2D, being a chronic illness, is widely documented to have a number of negative repercussions, including macrovascular and microvascular problems. Although the etiology of T2D is still unknown, there is growing evidence that inflammatory pathways are key and common pathogenic mediators in the natural course of diabetes [3].

The clinical presentation, underlying pathophysiology, and disease progression in diabetic patients can vary greatly between individuals, and atypical symptom presentation can sometimes make T2DM classification problematic. Many people with T2DM are asymptomatic at the time of diagnosis, while others present with severe hyperglycaemia or even diabetic ketoacidosis. The American Diabetes Association (ADA) Consensus Conference10 advised that high-risk people with IGT or IFG levels (HbA1c >6.5%; BMI 30 kg per m2; age 60 years) be treated with metformin. Pioglitazone11, as well as the combination of low-dose metformin and rosiglitazone, are also particularly effective in reducing the progression of prediabetes to diabetes. Weight reduction and exercise, while initially helpful, are connected with weight rebound in the majority of people [2, 4]. The organs involved in T2DM development include the pancreas (β-cells and α-cells), liver, skeletal muscle, kidneys, brain, small intestine, and adipose tissue.

Literature Review on Polypill Treatment Strategy

Aspirin, a statin, and blood pressure (BP)-lowering medications are likely currently being given to individuals with established cardiovascular disease, according to recommendations. To decrease prescription gaps and non-adherence, it would be appropriate to combine these pharmaceuticals into a cardiovascular polypill for these patients. Our goal was to determine how frequently individuals with type 2 diabetes (DM2) or existing cardiovascular diseases (CVD) used aspirin, statins, and other BP-lowering medications between 1996 and 2009. A significant percentage of patients with chronic cardiovascular illnesses already employ a mix of pharmaceutical treatments. To decrease prescription gaps and improve adherence to recommended therapy, it might be possible to introduce a polypill in high-risk patients.

Considerations and Challenges

In T2DM, using a polypill can help to simplify drug regimens and increase adherence to therapy. The use of polypill components such as aspirin, a statin, and blood pressure-lowering medicines in combination has been advocated for the prevention of cardiovascular disease in T2DM patients. The usage of a polypill can lessen pill burden for patients and potentially enhance drug adherence. The combined use of polypill components has increased over time, showing their importance in T2DM patients [9].

Individualized Treatment: T2DM is a complex disease that requires individualized treatment approaches. While a polypill can simplify medication regimens, it may not address the specific needs of each patient. Tailoring treatment to individual patients’ characteristics and preferences is essential for optimal management of T2DM.

Side Effects and Interactions: Combining multiple medications into a single pill increases the risk of side effects and drug interactions. Careful consideration should be given to the selection and dosing of medications in a polypill to minimize these risks and ensure patient safety.

Regulatory Approval: The use of a polypill in T2DM represents an innovative approach to enhance patient care and improve outcomes in the management of this chronic disease. The combined use of polypill components has shown an increasing trend over time, indicating its relevance in patients with T2DM. However, further research is needed to address individualized treatment approaches, potential side effects, and drug interactions. Regulatory approval and widespread availability of a T2DM-specific polypill are also important considerations. Overall, the concept of a polypill in T2DM holds promise in improving medication adherence and simplifying treatment regimens [10].

Future Aspects of Polypill in Type II Diabetes Mellitus

In type 2 diabetic mellitus (T2DM), the future prospects of a polypill show promise in enhancing patient adherence and eliminating gaps between indicated and used therapy, improving medication adherence, and simplifying treatment regimens. The combined use of polypill components has increased over time, showing their importance in T2DM patients. More research is needed, however, to address specific treatment options, potential adverse effects, and drug interactions. Important considerations include regulatory approval and broad availability of a T2DM-specific polypill. Overall, the polypill concept in T2DM is a unique strategy to improving patient care and outcomes in the management of this chronic condition. T2DM management necessitates a combination of lifestyle adjustments, medication adherence, and frequent monitoring. Adherence to many drugs, on the other hand, might be difficult for patients, resulting in inadequate disease control. The idea of a polypill, which mixes many prescriptions into a single pill, has garnered traction as a viable solution for improving adherence and simplifying treatment regimens [4].

The Future Scope of the Polypill Approach in T2DM Treatment Includes

Development of New Polypills: The development of new polypills that combine various medications for the treatment of T2DM is an area of active research. The efficacy and safety of these polypills need to be evaluated in clinical trials before they can be used in clinical practice. Personalized Polypills: The development of personalized polypills that are tailored to the individual needs of patients with T2DM is another area of active research. These polypills can be customized to include medications that are specific to the patient’s risk factors and comorbidities. Cost-Effective Treatment: The polypill approach can reduce the cost of T2DM treatment by reducing the number of medications required to control various risk factors and comorbidities. The development of cost-effective polypills can improve access to T2DM treatment for patients in low- and middle-income countries. Prevention of T2DM: The polypill approach can also be used for the prevention of T2DM by combining medications that target various risk factors associated with the development of T2DM. The polypill can simplify the prevention of T2DM by reducing the number of medications required for the prevention of various risk factors [5].

This strategy would increase the frequency of clinical examinations for vulnerable people while potentially raising costs; however, this increase could be mitigated by savings from fewer prescriptions and the anticipated reduction in adverse occurrences. As a result, clinical performance measures that combine therapy deintensification with correct clinical assessments and monitoring appear to be appropriate for safely terminating unnecessary and potentially harmful medicines while maintaining the benefits of vascular prophylaxis. This strategy will be crucial in establishing effective personalized preventive interventions for the aged and vulnerable [11]. Polypills are important in therapeutic practice, even if their contribution to increased adherence is small. A variety of other patient- and system-related characteristics, including as patient age, health literacy, socioeconomic level, disease and medication convictions, adverse effects, medical condition and degree, treatment expenses, and clinical outcomes, all contribute to positive outcomes [12]. However, reducing pill regimens, especially in cases when the number of tablets may be overwhelming for patients, may result in increased treatment adherence and, as a result, improved clinical results. Nonetheless, more long-term randomized controlled trials addressing a variety of medical problems will be needed to better understand the role of polypills in clinical practice [13, 14].